Searle Company Limited, a prominent Pakistani pharmaceutical company, has announced exceptional financial results for the first quarter ending September 30, 2025. The company’s profit skyrocketed by an impressive 183.8%, reaching Rs. 853.5 million compared to just Rs. 300.8 million during the same period last year.
This means the company nearly tripled its profits in just three months, which is remarkable growth in such a short time. Shareholders also benefited significantly, with earnings per share rising from Rs. 0.59 to Rs. 1.67.
The company’s total revenue also showed strong growth, increasing by 28.3% to reach Rs. 8.57 billion. This indicates that Searle sold more products and generated more business during this quarter compared to last year.
One of the key factors behind this dramatic profit increase was the sharp reduction in finance costs. These costs, which include interest payments on loans and other borrowing expenses, dropped by 62%. This massive decrease meant the company kept much more money as profit instead of paying it to lenders.
While the company did face higher distribution and administrative expenses, costs related to selling products and running the business, these increases were more than offset by other positive factors. The company maintained strong gross profit margins and benefited greatly from lower borrowing costs.
These results demonstrate that Searle Company has managed its costs efficiently and improved its overall operational performance.
The combination of growing sales, reduced finance costs, and effective management has delivered outstanding results for the company and its shareholders during this quarter.
